NO20001403L - Substituerte kromanderivater - Google Patents

Substituerte kromanderivater

Info

Publication number
NO20001403L
NO20001403L NO20001403A NO20001403A NO20001403L NO 20001403 L NO20001403 L NO 20001403L NO 20001403 A NO20001403 A NO 20001403A NO 20001403 A NO20001403 A NO 20001403A NO 20001403 L NO20001403 L NO 20001403L
Authority
NO
Norway
Prior art keywords
alkyl
substituted
conr
enantiomers
cycloalkyl
Prior art date
Application number
NO20001403A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001403D0 (no
Inventor
Stefan Berg
Mats Torbjoern Linderberg
Svante Ross
Seth-Olov Thorberg
Bengt Ulff
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20001403D0 publication Critical patent/NO20001403D0/no
Publication of NO20001403L publication Critical patent/NO20001403L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20001403A 1997-09-18 2000-03-17 Substituerte kromanderivater NO20001403L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703378A SE9703378D0 (sv) 1997-09-18 1997-09-18 New compounds
PCT/SE1998/001604 WO1999014213A1 (fr) 1997-09-18 1998-09-09 Derives de chromane substitue

Publications (2)

Publication Number Publication Date
NO20001403D0 NO20001403D0 (no) 2000-03-17
NO20001403L true NO20001403L (no) 2000-05-18

Family

ID=20408298

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001403A NO20001403L (no) 1997-09-18 2000-03-17 Substituerte kromanderivater

Country Status (23)

Country Link
US (2) US6387899B1 (fr)
EP (1) EP1025096B1 (fr)
JP (1) JP4002392B2 (fr)
KR (1) KR20010024078A (fr)
CN (1) CN1278809A (fr)
AR (1) AR016651A1 (fr)
AT (1) ATE255099T1 (fr)
AU (1) AU9193398A (fr)
BR (1) BR9812239A (fr)
CA (1) CA2303926A1 (fr)
DE (1) DE69820103T2 (fr)
EE (1) EE200000144A (fr)
HR (1) HRP20000133A2 (fr)
HU (1) HUP0100276A3 (fr)
IL (1) IL135074A0 (fr)
IS (1) IS5403A (fr)
NO (1) NO20001403L (fr)
PL (1) PL339661A1 (fr)
SE (1) SE9703378D0 (fr)
SK (1) SK2872000A3 (fr)
TR (1) TR200000737T2 (fr)
WO (1) WO1999014213A1 (fr)
ZA (1) ZA987806B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
BR0206513A (pt) 2001-01-16 2004-01-06 Astrazeneca Ab Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
MXPA03006250A (es) 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos heterociclicos terapeuticos.
NZ526699A (en) * 2001-01-16 2005-03-24 Astrazeneca Ab 8-amino derivatives and their use in treating migraine
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
GB0124020D0 (en) * 2001-10-05 2001-11-28 Astrazeneca Ab Chemical compounds
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (fr) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Utilisation d'alpha-tocotrienol pour le traitement de maladies mitochondriales
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
KR100681453B1 (ko) * 2005-03-22 2007-02-12 태남자동화기기 주식회사 권종 분류 기능을 구비한 지폐 방출기
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
WO2008130323A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 8-pipérazine-tétrahydronaphtalène utilisés pour le traitement de la douleur
WO2008130322A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 5-hétérocyclyl-chromane utilisés pour le traitement de la douleur
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
WO2008130321A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 807
WO2008130319A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 805

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012795A1 (fr) * 1989-04-27 1990-11-01 The Upjohn Company 3-amino chromanes substitues
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
JPH11511156A (ja) 1995-08-11 1999-09-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ビフェニル(チオ)アミドおよびビフェニルエタン(チオ)オン誘導体、その製造方法ならびに5−ht▲下1d▼ 受容体拮抗薬としてのその使用

Also Published As

Publication number Publication date
TR200000737T2 (tr) 2000-09-21
IS5403A (is) 2000-03-14
JP2001516755A (ja) 2001-10-02
ZA987806B (en) 1999-03-18
HRP20000133A2 (en) 2001-12-31
HUP0100276A3 (en) 2002-08-28
WO1999014213A1 (fr) 1999-03-25
DE69820103D1 (de) 2004-01-08
SK2872000A3 (en) 2000-11-07
NO20001403D0 (no) 2000-03-17
DE69820103T2 (de) 2004-09-02
AR016651A1 (es) 2001-07-25
ATE255099T1 (de) 2003-12-15
IL135074A0 (en) 2001-05-20
CA2303926A1 (fr) 1999-03-25
SE9703378D0 (sv) 1997-09-18
EP1025096B1 (fr) 2003-11-26
US6387899B1 (en) 2002-05-14
CN1278809A (zh) 2001-01-03
BR9812239A (pt) 2000-07-18
PL339661A1 (en) 2001-01-02
HUP0100276A2 (hu) 2002-05-29
AU9193398A (en) 1999-04-05
EP1025096A1 (fr) 2000-08-09
EE200000144A (et) 2001-02-15
JP4002392B2 (ja) 2007-10-31
KR20010024078A (ko) 2001-03-26
US6384225B1 (en) 2002-05-07

Similar Documents

Publication Publication Date Title
SE9702799D0 (sv) New compounds
NO20001402L (no) Substituerte kromanderivater
SE9703378D0 (sv) New compounds
CA2674548A1 (fr) Nouveau derive n-(2-aminophenyl)benzamide presentant une structure d'uree
NO20055316L (no) Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike
YU40998A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
DE69633607D1 (de) Piperidinderivate mit tachykinin-antagonistischer wirkung
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
NO20061419L (no) Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser
AR049739A1 (es) Derivados de aril-piridina
JP2016524597A (ja) 選択的ヒストン脱アセチル化酵素抑制剤としての新規化合物およびこれを含む薬剤学的組成物
PE20010482A1 (es) Derivados de 3-ureido-pirazol y procedimiento para su preparacion
BG105271A (bg) Производни на 1h-имидазопиридин
NO20072116L (no) Farmasoytiske forbindelser
RU2005113153A (ru) Новые пиримидинамидные производные и их применение
NO20071198L (no) N-(1H-indolyl)-1H-indol-2-karboksamidderivater, deres fremstilling og terapeutiske anvendelse
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
SE0101579D0 (sv) New compounds
PT1216245E (pt) Derivados sulfonil-hidrazida farmaceuticamente activos
RU2008145597A (ru) Гетероциклические арилсульфоны, пригодные для лечения расстройств, которые отвечают на модулирование 5-ht6 рецепторов
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
NO994340L (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
CO5720994A2 (es) Derivados sustituidos del pirrol
EA200001009A1 (ru) Производные пиридина, ингибирующие фосфодиэстеразу iv
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application